AGTC Genomics Unveils Breakthrough Clinical Validation Data at AACR Annual Meeting 2026 Demonstrating Strong Performance of Multi-Cancer Early Detection (MCED)

San Diego, USA – April 2026 — AGTC Genomics today announced the latest breakthrough clinical validation data at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22, 2026 in San Diego, USA, one of the world’s most prestigious platforms for cutting-edge cancer research.

The study highlights the strong clinical performance of AGTC Genomics’ CancerScreenDx Multi-Cancer Early Detection (MCED) test using circulating cell-free DNA (cfDNA), reinforcing its potential as a scalable and non-invasive cancer screening solution.

Robust Accuracy for Real-World Screening

The multi-centre clinical validation study, comprising 2,342 cancer patients and 1,646 non-cancer individuals, demonstrated:

• Overall Sensitivity: 83.1%

• Specificity: 95.4%

• Low False Positive Rate: 4.6%

These results underscore the test’s ability to accurately distinguish cancer from non-cancer individuals—meeting key performance thresholds required for population-level screening.

Strong Early Detection Capability

Early detection remains the most critical factor in improving cancer survival. The study showed:

• Stage I–II Sensitivity: 75.0% – 91.3%

• Stage III–IV Sensitivity: 95.5% – 100%

Importantly, the MCED assay demonstrated strong detection performance across multiple high-burden cancers relevant to Asia, including liver, gastric, pancreatic, bile duct, and nasopharyngeal cancers—areas where early diagnosis is often challenging.

Advanced Multi-Modal Genomic Approach

AGTC Genomics’ MCED platform integrates:

• Targeted cfDNA mutation profiling

• Genomic signature analysis

• AI-driven machine learning algorithms

This integrated approach enables detection of cancer signals from a simple blood draw, offering a non-invasive, radiation-free alternative to conventional screening methods.

Global Validation on a Prestigious Platform

The presentation at AACR 2026—recognized globally as a premier forum for breakthrough oncology research—marks a significant milestone for AGTC Genomics in advancing precision oncology innovation from Asia to the world.

Prof. Dr. Chee-Onn Leong, Founder and CEO of AGTC Genomics, said:

“The true significance of these results lies not just in the numbers, but in what they enable. We are moving toward a future where cancer can be detected earlier, more accurately, and more equitably. This is a foundational step toward precision public health—where advanced genomics is translated into real-world impact at scale.”

Transforming Cancer Screening Paradigm

The findings support MCED as:

• A single-test solution for detecting multiple cancers

• A complementary tool to existing screening programs

• A population-scale strategy to shift cancer detection earlier

By enabling earlier diagnosis, MCED has the potential to significantly reduce cancer mortality and healthcare burden across the region.

---

About AGTC Genomics

AGTC Genomics is a leading precision medicine company headquartered in Malaysia, specializing in next-generation sequencing (NGS) and multi-omics solutions for oncology, rare diseases, and population health. With ISO 15189-accredited laboratory capabilities and advanced genomic platforms, AGTC Genomics is committed to delivering high-quality, affordable, and locally accessible genomic solutions across Asia.